Researchers conducted a 24-week study involving 75 people who had chronic migraine and were already taking botulinum toxin injections. These participants added atogepant, taken once daily, to their existing treatment plan. The goal was to see if combining these two different types of medicines would further reduce the number of migraine and headache days.
During the study, participants experienced an average reduction in monthly migraine days. By the end of the 24 weeks, about 62% of people saw at least a 50% reduction in their migraine days. Headache days also decreased steadily over the course of the trial. Most participants reported that the treatment was safe and generally well-tolerated.
Some side effects were noted, with constipation, nausea, and urinary tract infections occurring in about 8% to 16% of people. Only two participants stopped the drug because of side effects. However, because this was a small study with only one group of patients, the results should be viewed as promising but not yet definitive. More research is needed to confirm these findings in larger groups.